Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

KRN 5500

Known as: 6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine, KRN-5500, KRN5500 
A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces… 
National Institutes of Health

Related topics

Related topics

6 relations
Cell Differentiation processEndoplasmic ReticulumGolgi ApparatusPositive Regulation of Apoptosis
Expand

Broader (1)

Purine Nucleosides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial.
CONTEXT Neuropathic pain in patients with cancer can be difficult to treat effectively. OBJECTIVES The purpose of the study was… 
  • figure 1
  • figure 2
  • table 2
  • table 1
  • table 3
2004
2004
A Phase I Clinical Trial of Spicamycin Derivative KRN5500 (NSC 650426) Using a Phase I Accelerated Titration “2B” Design
The spicamycin derivative KRN5500 was considered as a potential anti-cancer agent based on in vitro and preclinical studies. A… 
2003
2003
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
Therapy of B-cell chronic lymphocytic leukemia (CLL) is currently palliative, emphasizing the need for identification of new… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2003
2003
A Single Intravenous Injection of KRN5500 (Antibiotic Spicamycin) Produces Long-Term Decreases in Multiple Sensory Hypersensitivities in Neuropathic Pain
Neuropathic pain is a significant clinical problem. Currently, there are no drugs that produce complete amelioration of this type… 
  • figure 1
  • figure 2
  • figure 4
  • figure 5
2002
2002
Incorporation of the Anticancer Agent KRN5500 into Polymeric Micelles Diminishes the Pulmonary Toxicity
KRN5500 is a highly active new semi‐synthetic water‐insoluble anticancer agent. The only mechanism of anticancer activity of… 
  • figure 1
  • table I
  • figure 2
  • figure 3
2001
2001
Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study
Abstract. Purpose: KRN5500, a novel spicamycin derivative, shows the greatest activity against a human tumor xenograft model and… 
Highly Cited
1999
Highly Cited
1999
Reduction of the Side Effects of an Antitumor Agent, KRN5500, by Incorporation of the Drug into Polymeric Micelles
For intravenous (i.v.) injection of a water‐insoluble antitumor drug, KRN5500, we have successfully incorporated KRN5500 into… 
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table II
1997
1997
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
The spicamycin analogue KRN5500 (NSC 650426; SPA) is derived from Streptomyces alanosinicus. The unique structure contains a… 
  • figure I
  • figure 2
  • figure 3
  • figure 4
  • figure 5
1995
1995
In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Spicamycin (SPM), produced by Streptomyces alanosinicus, induces potent differentiation in a human leukemia cell line, HL60. One… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
1994
1994
Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
KRN5500, (6-[4-Deoxy-4-(2E,4E)-tetradecadienoylglycyl]amino-L-glycero - beta-L-mannoheptopyranosyl]amino-9H-purine), was semi… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE